T 0605/20 (Peptide formulations/NOVO NORDISK) of 11.11.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T060520.20221111
- Date of decision
- 11 November 2022
- Case number
- T 0605/20
- Online on
- 12 December 2022
- Petition for review of
- -
- Application number
- 04797453.0
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on EPC2000 Art 056
- Application title
- PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES
- Applicant name
- NOVO NORDISK A/S
- Opponent name
- Sandoz AG
Fresenius Kabi Deutschland GmbH
Wittkopp, Alexander
Teva Pharmaceutical Industries Ltd.
Generics (U.K.) Limited
Uexküll & Stolberg
Partnerschaft von Patent- und Rechtsanwälten mbB - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83
- Keywords
- Amendments - allowable (yes)
Sufficiency of disclosure - (yes)
Novelty - selection invention
Inventive step - formulation of the technical problem - Catchword
- The undesired phenomena observed in the patent with the use of the prior art compositions would not inevitably manifest themselves upon the practical implementation of the teaching of the prior art. The recognition of the relevance of these phenomena should therefore be considered to form part of the technical contribution described in the patent. A specific reference in the formulation of the objective technical problem to the avoidance of these phenomena risks to unfairly direct development towards the claimed solution, which is not permissible in line with the principles as developed in the established jurisprudence (see reasons section 4.2.3).
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed